Inflammasome (NLRP3) Antibody Sampler Pack

Inflammasome (NLRP3) Antibody Sampler Pack

The Inflammasome (NLRP3) Antibody Sampler Pack from Assay Genie brings together 8 rigorously validated antibodies spanning the key nodes of this pathway, supplied in a convenient 20µL trial size. It lets researchers screen an entire signalling axis in a single, cost-effective pack — validated for applications including ELISA, IF/ICC, IP, WB — before committing to full-size vials. Each antibody is also available individually in a full 100µL size.

Inflammasomes are cytosolic multiprotein platforms that couple detection of infection and cellular damage to the maturation of proinflammatory cytokines and an inflammatory form of cell death. The NLRP3 inflammasome is the most extensively studied, responding to a remarkably broad range of danger signals including microbial toxins, extracellular ATP, crystalline material, and disturbances in ionic and mitochondrial homeostasis. Its activation typically requires two steps: a priming signal that upregulates NLRP3 and pro-IL-1beta, and an activation signal that licenses assembly. Upon activation, NLRP3 oligomerizes and recruits the adaptor ASC/PYCARD through pyrin-domain interactions, nucleating helical ASC filaments that condense into a perinuclear speck. ASC in turn recruits pro-Caspase-1 via caspase-recruitment domains, driving its proximity-induced autoproteolysis into active Caspase-1. The serine-threonine kinase NEK7 is an essential licensing factor that binds NLRP3 and bridges adjacent subunits to enable oligomerization, linking inflammasome assembly to the cell cycle. Active Caspase-1 cleaves the precursors of the potent pyrogenic cytokines IL-1beta and IL-18 into their bioactive forms and cleaves gasdermin D, whose liberated N-terminal fragment perforates the plasma membrane to release these cytokines and execute pyroptosis. A related sensor, AIM2, detects cytosolic double-stranded DNA and assembles an ASC- and Caspase-1-dependent inflammasome through a distinct, non-NLR mechanism, broadening surveillance to nucleic-acid danger. Excessive or chronic inflammasome activity drives gout, atherosclerosis, metabolic disease, and inherited autoinflammatory syndromes, making these components attractive therapeutic targets. Resolving the priming, assembly, and effector phases demands reagents recognizing each module. This sampler pack brings together validated antibodies against NLRP3, ASC/PYCARD, Caspase-1, IL-1beta, IL-18, Gasdermin D, NEK7, and AIM2 for studying inflammasome assembly and downstream inflammatory output.